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A 10-year-old boy was referred with developmental delay and dysmorphism. Genomewide aCGH microarray analysis detected
a de novo 3.7Mb deletion at 1q32.1: arr 1q32.1(199,985,888-203,690,832)x1 dn [build HG19]. This first report of a deletion in this
region implies a critical role for dosage-sensitive genes within 1q32.1 in neurological development.This is consistent with previously
reported duplications of this region in patients with a similar phenotype.
1. Introduction
Developmental delay with or without dysmorphism is the
most common referral for microarray analysis in the cytoge-
netic laboratory; and microarray analysis is a critical tool for
identifying copy number changes in these patients. Deletions
of 1q32.1 have not previously been reported in the literature.
2. Case Presentation
The patient was presented for genetic testing at 10 years
of age with dysmorphic features and intellectual disability
(Figure 1). He was born at term from a first uneventful
pregnancy without perinatal complications. Birth weight was
3450 g (50th centile), length 51 cm (50th centile), and head
circumference 35 cm (50th centile). At 12 months of age he
had global developmental delay and was able to sit. He was
able to walk at 18months but had difficulties with social skills.
On examination at the age of 4 years, his head circumfer-
ence was 51 cm (50th centile) and the other growth param-
eters were also normal. Dysmorphic features included a
long face, narrow jaw, downslanted palpebral fissures, highly
arched eyebrows, low-set ears, thick lower lip, bilateral fifth
finger clinodactyly, and proximal placement of the thumb.
Neurological assessment revealed generalized hypotonia and
reduced deep tendon reflexes.
Neuropsychological evaluation was performed at 7 years
of age. A full scale IQ of about 50 was established by the
Woodcock-Johnson Tests of Cognitive Abilities, and the
Bender Visual Gestalt Test revealed difficulties in visual-
motor coordination. Speech evaluation indicated significant
difficulties with receptive and expressive language; how-
ever a slow improvement in language acquisition has been
observed. At the age of 10 years he requires special education
and support in everyday life.
Routine EEG and brain MRI were normal. Fragile X
syndrome testing, karyotype, and screening for inborn error
of metabolism by blood MS/MS and urine GC/MS, serum
CK, and lactate/pyruvate were all normal.
Both parents are healthy and have no other children.
There is no history of intellectual disability in the family.
Genomewide array CGH analysis using the Nimblegen
135 K WG CGH v3.1 platform (with a minimal resolution of
0.2Mb) identified a 3.7Mb copy number loss on the long
arm of chromosome 1: arr 1q32.1(199,985,888-203,690,832)x1
[build HG19]. DNA was extracted from blood samples using
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Figure 1: The patient at 10 years of age.
the Nucleon (Amersham) and Genomic DNA Purification
kits (Gentra) according to the manufacturer’s instructions.
The microarray was washed and then scanned on an Axon
GenePix 4400A Scanner using GenePix Pro 7 software
(Molecular Devices, Sunnyvale, CA, USA). Raw data was
normalized and LOESS correction applied and the data ratios
were calculated using DEVA v1.01 Software (Roche Nimble-
Gen). The normalized data was processed using Infoquant
Fusion v6.0 software (Infoquant, London, UK) with analysis
call settings of 3 consecutive probes ±0.4 Cy3/Cy5 ratio.
Themicroarraywas carried out using sexmatched control
DNA and confirmed by qPCR analysis using primers from
the ELF3 gene locus and FISH using probe RP11-134G8
(BlueGnome). Parental testing using the same qPCR and
FISH probes as the proband showed the deletion to be de
novo in origin.
3. Discussion
To our knowledge, no deletions of a similar size or location
have been reported previously in the literature, and there
were no similar-sized deletions found in our internal lab-
oratory database or ECARUCA (European Cytogeneticists
Association Register of Unbalanced Chromosome Aber-
rations). DECIPHER (Database of Chromosomal Imbal-
ance and Phenotype in Humans Using Ensembl Resources,
https://decipher.sanger.ac.uk/ (accessed 13/01/2016)) revealed
one patient (ref: 259811) with a de novo, smaller (2.59Mb)
deletion but with no phenotypic or predicted pathogenicity
information available. A second DECIPHER patient (ref.
288679)was identifiedwithmacroglossia, intellectual disabil-
ity, and a larger (5.95Mb) deletion of unknown inheritance,
partially overlappingwith the region of interest in our patient.
A third patient was identified from the ISCA (International
Standards for Cytogenetic Arrays) database (ref. nssv575720),
presenting with developmental delay and a 3Mb (likely
pathogenic) deletion of unknown inheritance. Searching of
theDGV (Database of GenomicVariants) indicated that copy
number loss is not present in normal individuals.
Duplications within the same region have been associ-
ated with global developmental delay, behavioural problems,
paraesthesias, staring spells, headaches, motor difficulties,
and myoclonic epilepsy [1]. In the Olson study, KDM5B,
NAV1, and KIF21B were identified as candidate genes for
developmental delay from two patients with microduplica-
tions of 1q32.1, and these genes are all common to the deleted
region of our patient. They have been reported with an HI
index [2] (% haploinsufficiency scores) of 28%, 16%, and 38%,
respectively, where the lower the percentage score, the greater
the chance that haploinsufficiency will have a phenotypic
impact.
In total, 59 genes are located within the deleted region
in our patient, of which GPR37L1 and SYT2 (in addition to
the three previously mentioned) are expressed in neuronal
tissues.
KDM5B is a histone lysine demethylase which is involved
in cell maintenance and repair and may have a role in
embryonic development [1]. NAV1 is amember of the neuron
navigator family which is expressed predominantly in the
brain. These navigators are microtubule plus-end tracking
proteins which have also been shown to induce the formation
of neurite-like extensions in nonneuronal cells and thus have
the ability to affect the cytoskeleton [3]. The KIF21B protein
is a member of the kinesin family and is a microtubule
motor protein also highly expressed in neuronal tissue [1].
GPR37L1 encodes an orphan G protein coupled receptor
which is activated by the protein prosaposin.This protein has
a protective effect on the neurons and glia in the nervous
system [4]; and missense mutations of SYT2 have been
associated with myasthenic syndrome, a disorder of the
peripheral motor nerve terminal which gives rise to variable
limb weakness and reduced deep tendon reflexes [5]. All five
of these genes are also deleted in the patient from the ISCA
database and from both DECIPHER patients.
It is therefore possible that there is a dosage effect for one
ormore of these genes whichmay be causative of the patient’s
clinical features.
Our literature search did not reveal any genes from this
region with a clear association between copy number loss
and dysmorphism. Although we cannot exclude unknown
gene functions or gene dosage effects, it is possible that
this patient’s dysmorphism may be coincidental to the copy
number loss.
Genes which are expressed in neurological tissues are
present in this novel 1q32.1 region of de novo copy number
loss. These genes have also been identified in duplications of
the same region in patients with a shared phenotype. This
implies that for one or more genes in this region, dosage
sensitivity as a result of either haploinsufficiency or triplosen-
sitivity impacts on the neurodevelopmental phenotype in
ways not yet understood.
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